Syphilis Treatment Protocol

Similar documents
Syphilis: Aid to Diagnosis

California Guidelines for STD Screening and Treatment in Pregnancy

Congenital Syphilis. RPA Newborn Care Guidelines Royal Prince Alfred Hospital. Introduction. Incidence and Risk Factors. Clinical Features 1, 2

Zika Virus. Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases

Syphilis. Communicable Disease Management Protocol. 1. Etiology. 2. Case Definitions

TREATMENT OF STI CONTACTS

Syphilis Fast latex Agglutination Test: A Rapid Confirmatory Test for Syphilis

Diagnosis and Treatment Regimes for Syphilis By Dr John Bannister

Leader's Resource. Note: Both men and women can have an STD without physical symptoms.

Immunization Healthcare Branch. Human Papillomavirus Vaccination Program Questions and Answers. Prepared by

Direct Testing Systems and Serology

Frequently Asked Questions

THIS IS AN OFFICIAL NH DHHS HEALTH ALERT

SOGC recommendation on ZIKA virus exposure for clinicians caring for pregnant women and those who intend to get pregnant

Sexually Transmitted Infections (STI) One Day Update

Frequently Asked Questions

STANDARD PROTOCOL STD AND HIV SCREENING AND EPIDEMIOLOGIC STD TREATMENT

Rapid Plasma Reagin (RPR) for detection of syphilis antibodies

2014 CDC Treatment Guidelines for STDs What s New, What s Important, What s Essential. STD Treatment Guidelines. How are the guidelines prepared?

The Minnesota Chlamydia Strategy: Action Plan to Reduce and Prevent Chlamydia in Minnesota Minnesota Chlamydia Partnership, April 2011

Yes, I know I have genital herpes:

CDC 2015 STD Treatment Guidelines: Update for IHS Providers Sharon Adler M.D., M.P.H.

Syphilis. Looking after your sexual health

Fact Sheet for Health Care Providers: Interpreting Results from the Aptima Zika Virus Assay. June 17, 2016

Rhode Island Department of Health Division of Infectious Diseases and Epidemiology

Syphilis on the rise again in Germany results from surveillance data for 2011

Homework 5: Differential Diagnosis of Multiple Sclerosis

Accent on Health Obgyn, PC HERPES Frequently Asked Questions

HPV Vaccines. What is HPV? Can a vaccine help prevent HPV?

4/30/2013 HPV VACCINE AND NORTH DAKOTA HPV IMMUNIZATION RATES HUMAN PAPILLOMAVIRUS (HPV) HUMAN PAPILLOMAVIRUS HPV CONTINUED

ARIZONA SEXUALLY TRANSMITTED DISEASE OUTBREAK RESPONSE PLAN

HIV/AIDS: General Information & Testing in the Emergency Department

Commonly Asked Questions About Chronic Hepatitis C

Preface. TTY: (888) or Hepatitis C Counseling and Testing, contact: 800-CDC-INFO ( )

Diseases that can be spread during sex

Other Causes of Fever

AIR FORCE REPORTABLE EVENTS GUIDELINES & CASE DEFINITIONS

Sexually Transmitted Infections (STIs) and the STI Clinic

WA Endemic Regions STI/HIV Control Supplement

What is HPV? Low-risk HPV types. High-risk HPV types

The challenge of herpes

Sexual Health and Sexually Transmitted Infections Prevention and Control Protocol, 2013 (Revised)

William Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016

2010 STD Treatment Guidelines: Update for Primary Care Providers

Eastern Health MS Service. Tysabri Therapy. Information for People with MS and their Families

Coding and Billing for HIV Services in Healthcare Facilities

35-40% of GBS disease occurs in the elderly or in adults with chronic medical conditions.

12/2/2015 HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE OBJECTIVES VIRAL HEPATITIS

FREQUENTLY ASKED QUESTIONS ABOUT PERTUSSIS (WHOOPING COUGH)

MUMPS PUBLIC FREQUENTLY ASKED QUESTIONS

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

STD Treatment Chart Nancy Harris, N.P. Women s Health Coordinator August 2003 Disease Treatment Alternative treatment

Appendix 1 Sensitivity, Specificity and Predictive Values of Diagnostic Tests

HIV/AIDS. HIV- Human Immunodeficiency Virus. AIDS immume system severely damaged

Chlamydia THE FACTS. How do people get Chlamydia?

Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management

Expedited Partner Therapy (EPT) for Sexually Transmitted Diseases Protocol for Health Care Providers in Oregon

Serological diagnosis of syphilis

Pap smears, cytology and CCHC lab work and follow up

A guide for people with genital herpes

TUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG

Changes in the 2010 STD Treatment Guidelines: What Adolescent Health Care Providers Should Know February 2011

Guidelines for TB Blood Testing. Minnesota Department of Health TB Prevention and Control Program June 2011

HPV and HPV Testing. Human Papilloma Virus (HPV) What are viruses? What is HPV?

Treatment of sexually transmitted and other genital infections

CMV: Your questions answered

APPENDIX I-A: INFORMED CONSENT BB IND Protocol CDC IRB #4167

Parvovirus B19 Infection in Pregnancy

CERVICAL CANCER What every woman should know What is a cervix?

Body Fluid Exposure:

Frequently Asked Questions: Pre-Exposure Prophylaxis (PrEP) for HIV Infection Massachusetts Department of Public Health Updated July 2013

Lyme Disease in Pregnancy. Dr Sarah Chissell Consultant Obstetrician William Harvey Hospital, Kent

Key Facts about Influenza (Flu) & Flu Vaccine

Testosterone Therapy for Women

The Basics of Drug Resistance:

GARPR Online Reporting Tool

PLUS MAY EQUAL. Flu-Like Symptoms SORE THROAT, SWOLLEN GLANDS, FEVER, JOINT AND MUSCLE ACHES

Laboratory confirmation requires isolation of Bordetella pertussis or detection of B. pertussis nucleic acid, preferably from a nasopharyngeal swab.

Preconception Clinical Care for Women Medical Conditions

Accent on Health Obgyn, PC HPV Frequently Asked Questions

Summary of Key Points WHO Position Paper on Vaccines against Human Papillomavirus (HPV) October 2014

Brain Cancer. This reference summary will help you understand how brain tumors are diagnosed and what options are available to treat them.

Outpatient/Ambulatory Health Services

POST-EXPOSURE PROPHYLAXIS IN THE HEALTH CARE SETTING

IF YOU ARE RECEIVING TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS (NATALIZUMAB)

Resource Document 6: Tetanus Immunization. I. Introduction

How can herpes simplex spread to an infant?

ALBERTA IMMUNIZATION POLICY GUIDELINES

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep)

Lyme (IgG and IgM) Antibody Confirmation

Congenital Toxoplasmosis Patient Scenario

POSTEXPOSURE PROPHYLAXIS

Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges

ALS and Lyme Disease Questions from Patient and Families Responses from Medical Experts

Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) (908)

Partner Services Providers. Quick Guide

Premarital Screening Standard. Premarital Screening and Counseling Program. Version 1.1

Zika virus infection: guidance for primary care

CVP Chemotherapy Regimen for Lymphoma Information for Patients

Transcription:

STD, HIV, AND TB SECTION Syphilis Treatment Protocol CLINICAL GUIDANCE FOR PRIMARY AND SECONDARY SYPHILIS AND LATENT SYPHILIS (4/2016) Page 1 of 8

Table of Contents Description... 3 Stages and Symptoms... 3 Primary infection:... 3 Secondary infection:... 3 Tertiary syphilis:... 3 Latent and late latent syphilis:... 4 Risk Factors... 4 Diagnosing Syphilis... 5 Serology:... 5 Cerebrospinal fluid (CSF) exam:... 6 Treatment of Syphilis... 6 Primary and secondary syphilis treatment:... 6 Late latent (infection of more than one year) or latent syphilis of unknown duration:... 7 Tertiary syphilis treatment:... 7 Special populations:... 7 Neurosyphilis and ocular syphilis:... 7 Follow up... 7 Management of Partners... 8 (4/2016) Page 2 of 8

Description Syphilis is a systemic disease caused by the spirochete Treponema pallidum. It is transmitted through sexual contact, but can also be transmitted from mother to fetus during pregnancy. Syphilis is divided into three stages; primary, secondary and latent or tertiary syphilis. Stages are determined by clinical findings, which are used to provide guidance for treatment and follow up. Syphilis affecting the central nervous system (CNS) can occur during any stage of syphilis. Stages and Symptoms Primary infection: Painless ulcers(s) or chancre(s) at the infection site Lesions are usually firm, round and painless Appear 10 to 90 days, with an average of 21 days, after exposure to syphilis Lesions may persist for 3 6 weeks then resolve Secondary infection: Rash often on the palms of hands, bottom of feet, on the torso or other sites Mucus membrane lesions or sores in the mouth, vagina, or anus Flat wart like growths, condylomata lata, in the perianal/genital area and other moist body sites Generalized lymphadenopathy, sore throat Alopecia Headaches Weight loss Muscle aches Fatigue Onset of symptoms typically occurs six weeks to six months after onset of the lesion or chancre (can overlap with primary stage) and resolves in 2 10 weeks. About 25 percent of people may have relapses of symptoms in the first year. Tertiary syphilis: Tertiary syphilis is defined as symptomatic late latent syphilis, gumma and cardiovascular syphilis, but not neurosyphilis. Damage to the heart, blood vessels, liver, bones and joints can develop Gummatous, soft noncancerous lesions, occur Uveitis or other ocular manifestations (4/2016) Page 3 of 8

Latent and late latent syphilis: Latent syphilis is defined as seroreactivity without other evidence primary, secondary or tertiary disease. Early latent, latent and late latent syphilis overlap the primary, secondary and tertiary stages of syphilis based on length of time of infection and visible symptoms. Latent syphilis acquired with the preceding year is classified as early latent syphilis. Criteria for early latent syphilis include a negative test in the past year, documented exposure to early syphilis in the past year and symptoms of syphilis that have resolved in the past year. Latent syphilis acquired more than one year ago or of unknown duration is classified as late latent syphilis. The majority of people with late latent syphilis may be asymptomatic for many years. Risk Factors Exposure to syphilis through oral, vaginal and anal sex Transmission from a pregnant woman to her fetus Lack consistent use of condoms with every sexual contact History of previous of STD diagnosis Multiple sex partners HIV infected persons Men who have sex with men Sexual partners of men who have sex with men Persons who exchange sex for drugs or money or having partners who do (male or female) Sexual assault victims Routine screening is recommended: Annually for men who have sex with men Person with HIV infection and at least every 6 months for those at higher risk Annually for individuals with multiple sex partners, or a partner who has multiple sex partners All pregnant women at: their first prenatal visit 28 32 weeks Delivery Any woman who has a fetal death after 20 weeks gestation should be tested for syphilis Any person with primary or secondary syphilis should be tested for HIV (4/2016) Page 4 of 8

Diagnosing Syphilis Darkfield examinations and tests to detect T. pallidum directly from lesion exudate or tissue are the definitive methods for diagnosing early syphilis. Presumptive diagnosis of syphilis requires use of two tests: a nontreponemal and a treponemal test. The nontreponemal is a quantitative measure and the treponemal is to confirm, both as part of diagnostic steps. Serology: Nontreponemal screening: Venereal Disease Research Laboratory Assay (VDRL), Rapid Plasma Reagin (RPR), or Unheated Serum Regain (USR) Nontreponemal results should be reported quantitatively. Nontreponemal antibody titers might correlate with disease activity and are used to follow treatment response. A fourfold change in titer, equivalent to a change of two dilutions (e.g. 1:16 to 1:4 or 1:8 to 1:32), is necessary to demonstrate a clinically significant difference between two nontreponemal test results obtained using the same serologic test. Nontreponemal test titers usually decline after treatment and might become nonreactive with time; however, in some persons, nontreponemal antibodies can persist for a long period of time, a response referred to as the serofast reaction Treponemal screening: Fluorescent Treponemal Antibody Absorption (FTA ABS), Treponemal Pallidum Particle Agglutination Assay (TT PA) Persons with a reactive nontreponemal test should always receive a treponemal test to confirm the diagnosis of syphilis. Persons with reactive treponemal test tests will usually have a reactive test result for a lifetime. Treponemal tests are done To confirm nontreponemal reactive results and At recent onset of suspicious new lesion Treponemal assays do not predict response to treatment and should not be used for this purpose. Treponemal tests by, Enzyme Immunoassay (EIA), chemiluminescence immunoassays (CIA) or Microbead Immunoassay (MIA) are a reverse screening algorithm for syphilis. This screening can identify persons previously treated for syphilis, those with untreated or incompletely treated syphilis and persons with false positive results that can occur with a low likelihood of infection. In persons with HIV infection serologic tests are accurate and reliable for diagnosing syphilis and following a patient s response to treatment. However, atypical nontreponemal serologic test results (i.e. unusually high, low, or fluctuating titers) might occur regardless of HIV infection status. When serologic tests do not correspond with clinical findings suggestive of early syphilis, presumptive treatment is recommended for person with risk for syphilis, and use of other tests (e.g., biopsy and PCR) should be considered. (4/2016) Page 5 of 8

Cerebrospinal fluid (CSF) exam: Further testing is warranted for persons with clinical signs of neurosyphilis, infection of the nervous system including the brain and spinal cord. Laboratory testing is helpful in supporting the diagnosis of neurosyphilis, but no single test can be used for diagnosis. A combination of (CSF cell count or protein or a reactive CSF VDRL) in the presence of reactive serologic test results and neurologic signs and symptoms should be used for diagnosis. CSF laboratory abnormalities are common in persons with early syphilis and are of unknown significance in the absence of neurologic signs. CSF VDRL is highly specific but insensitive Persons who have HIV infection, CSF leukocyte count usually is elevated ( 5 white blood [WBC]/mm³). Using a higher cutoff ( 20 WBC/mm³) might improve the specificity of neurosyphilis diagnosis. For more details on testing and interpreting test results see the CDC MMWR; Sexually Transmitted Diseases Treatment Guidelines, 2015 (http://www.cdc.gov/std/tg2015/default.htm), pages 34 35. Treatment of Syphilis Penicillin G administered intramuscularly (IM) or intravenously (IV) is the preferred drug for treating all stages of syphilis. The preparation used (i.e. benzathine, aqueous procaine or aqueous crystalline), dosage and length of treatment depend on the stage and clinical signs of the disease. Combinations of benzathine penicillin, procaine penicillin and oral penicillin preparations are not appropriate for the treatment of syphilis. Penicillin G administered IM or IV is the only therapy with documented efficacy for syphilis during pregnancy. Pregnant women in any stage of syphilis who report penicillin allergy should be desensitized and treated with penicillin. Primary and secondary syphilis treatment: Administer benzathine penicillin G (Bicillin L A) 2.4 million units Intramuscularly (IM) in a single dose For penicillin allergic persons administer regimens of: doxycycline 100 mg orally twice daily for 14 days or tetracycline 500 mg four times daily for 14 days. Compliance is likely to be better with doxycycline than tetracycline due to the gastrointestinal side effects and more frequent dosing of tetracycline. De not use Azithromycin as first line treatment for syphilis, it should be used with caution only when recommended treatment options are not feasible. Treatment failures with azithromycin have been documented in multiple geographic areas in the United States. Other management considerations include testing all persons who have latent syphilis for HIV and evaluating anyone with neurological signs and symptoms for neurosyphilis. (4/2016) Page 6 of 8

Late latent (infection of more than one year) or latent syphilis of unknown duration: Administer benzathine penicillin G (Bicillin L A) 7.2 million units total, administered as three doses of 2.4 million units IM each at one week intervals For penicillin allergic persons administer: doxycycline 100mg orally twice daily for 28 days or tetracycline 500mg orally four times daily for 28 days If compliance cannot be assured, the following regimen should be considered; Procaine penicillin G 2.4 million units IM once daily PLUS Probenecid 500mg orally four times a day, both for 10 14 days Tertiary syphilis treatment: Tertiary Syphilis with Normal CSF Examination Administer benzathine penicillin G (Bicillin L A) 7.2 million units total, three doses of 2.4 million units IM each at one week intervals All persons who have tertiary syphilis should be tested for HIV and receive a CSF examination before treatment is initiated Special populations: Pregnancy, Congenital Syphilis, Infants/Children See Sample Clinical Guidelines for Pregnancy, Congenital Syphilis and Infants/Children (http://www.health.state.mn.us/divs/idepc/diseases/syphilis/hcp/clinicalguidepc.pdf) HIV Infected Persons Persons with HIV infection with latent syphilis should be treated as persons who do not have HIV infection. Neurosyphilis and ocular syphilis: Administer aqueous crystalline penicillin G 18 24 million units per day, 3 4 million units IV every four hours or continuous infusion, for 10 14 days. For more details on treatment of syphilis see the CDC MMWR; Sexually Transmitted Diseases Treatment Guidelines, 2015 (http://www.cdc.gov/std/tg2015/clinical.htm), pages 36 44. Follow up Persons with primary and secondary syphilis should have both clinical and serologic evaluation at 6 and 12 months after treatment. Persons with HIV infection should have both clinical and serological evaluation for treatment failure at 3, 6, 9, 12, and 24 months. Persons with latent syphilis should have quantitative nontreponemal serologic tests repeated at 6, 12, and 24 months. CSF examination should be performed if serology fails to indicate response to treatment. For more details on Follow up, see the CDC MMWR; Sexually Transmitted Diseases Treatment Guidelines, 2015 (http://www.cdc.gov/std/tg2015/clinical.htm), pages 37 44. (4/2016) Page 7 of 8

Management of Partners All persons who have had sexual contact with persons with primary, secondary or latent syphilis should be examined clinically and serologically, and receive treatment based on: Persons who have had sexual contact with a person who receives a diagnosis of primary, secondary or early latent syphilis within 90 days preceding the diagnosis should be treated presumptively for early syphilis, even if the serologic test results are negative. Persons who have had sexual contact with a person who receives a diagnosis of primary, secondary, or early latent syphilis 90 days before the diagnosis should be treated presump vely for early syphilis of serologic test results are not immediately available and the opportunity for follow up is uncertain. If serologic tests are negative, no treatment is necessary. If serologic tests are positive, treatment should be based on clinical and serologic evaluation and stage of syphilis. Under Minnesota state law, physicians, health care facilities, and medical laboratories are required to report all laboratory confirmed cases of syphilis to the Minnesota Department of Health (MDH) [Minnesota Rules, part 4605.7030 7040]. MDH will make every attempt to contact the patient and to obtain partner information for follow up. Long term sex partners of persons who have late latent syphilis should be evaluated clinically and serologically for syphilis and treated on the basis of the evaluation s findings. Minnesota Department of Health STD, HIV, and TB Section 651 201 5414 www.health.state.mn.us/std To obtain this information in a different format, call: 651 201 5414 (4/2016) Page 8 of 8